ABIOMED Company Profile (NASDAQ:ABMD)

About ABIOMED (NASDAQ:ABMD)

ABIOMED logoABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology - NEC
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:ABMD
  • CUSIP: 00365410
  • Web: www.abiomed.com
Capitalization:
  • Market Cap: $6.8032 billion
  • Outstanding Shares: 43,895,000
Average Prices:
  • 50 Day Moving Avg: $146.15
  • 200 Day Moving Avg: $131.67
  • 52 Week Range: $95.14 - $157.41
P/E:
  • Trailing P/E Ratio: 90.36
  • Foreward P/E Ratio: 59.43
  • P/E Growth: 2.41
Sales & Book Value:
  • Annual Revenue: $474.78 million
  • Price / Sales: 14.28
  • Book Value: $12.92 per share
  • Price / Book: 11.96
Profitability:
  • EBIDTA: $110.92 million
  • Net Margins: 16.13%
  • Return on Equity: 13.03%
  • Return on Assets: 10.98%
Debt:
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 5.95%
  • Quick Ratio: 5.32%
Misc:
  • Average Volume: 316,162 shs.
  • Beta: 0.2
  • Short Ratio: 4.97
 
Frequently Asked Questions for ABIOMED (NASDAQ:ABMD)

What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

How were ABIOMED's earnings last quarter?

ABIOMED, Inc. (NASDAQ:ABMD) announced its earnings results on Thursday, July, 27th. The company reported $0.45 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.42 by $0.03. The firm had revenue of $132.47 million for the quarter, compared to the consensus estimate of $130.83 million. ABIOMED had a return on equity of 13.03% and a net margin of 16.13%. The firm's revenue for the quarter was up 28.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.29 EPS. View ABIOMED's Earnings History.

When will ABIOMED make its next earnings announcement?

ABIOMED is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for ABIOMED.

Where is ABIOMED's stock going? Where will ABIOMED's stock price be in 2017?

7 brokers have issued 12 month price objectives for ABIOMED's stock. Their predictions range from $140.00 to $175.00. On average, they anticipate ABIOMED's stock price to reach $157.50 in the next year. View Analyst Ratings for ABIOMED.

Who are some of ABIOMED's key competitors?

Who are ABIOMED's key executives?

ABIOMED's management team includes the folowing people:

  • Michael R. Minogue, Chairman of the Board, President, Chief Executive Officer
  • Michael J. Tomsicek, Chief Financial Officer, Vice President, Treasurer
  • David M. Weber, Chief Operating Officer
  • William J. Bolt, Senior Vice President, Global Quality, Regulatory and Clinical Operations
  • Andrew J. Greenfield, Vice President, General Manager - Global Marketing
  • Michael G. Howley, Vice President, General Manager - Global Sales and Marketing
  • Dorothy E. Puhy, Lead Independent Director
  • Jeannine M. Rivet, Independent Director
  • Eric A. Rose M.D., Independent Director
  • Martin P. Sutter, Independent Director

Who owns ABIOMED stock?

ABIOMED's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include PRIMECAP MANAGEMENT COMPANY (9.85%), BlackRock Inc. (7.69%), Vanguard Group Inc. (7.56%), Baillie Gifford & Co. (4.49%), Palo Alto Investors LLC (4.45%) and State Street Corp (2.44%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.

Who sold ABIOMED stock? Who is selling ABIOMED stock?

ABIOMED's stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Voya Investment Management LLC, Jackson Square Partners LLC, Russell Investments Group Ltd., William Blair Investment Management LLC, Macquarie Group Ltd., Arrowstreet Capital Limited Partnership and Marshall Wace North America L.P.. Company insiders that have sold ABIOMED stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Michael G Howley and Michael R Minogue. View Insider Buying and Selling for ABIOMED.

Who bought ABIOMED stock? Who is buying ABIOMED stock?

ABIOMED's stock was purchased by a variety of institutional investors in the last quarter, including Koch Industries Inc., Baillie Gifford & Co., FMR LLC, Renaissance Technologies LLC, Frontier Capital Management Co. LLC, State Treasurer State of Michigan, BlackRock Inc. and Castleark Management LLC. View Insider Buying and Selling for ABIOMED.

How do I buy ABIOMED stock?

Shares of ABIOMED can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ABIOMED's stock price today?

One share of ABIOMED stock can currently be purchased for approximately $154.51.


MarketBeat Community Rating for ABIOMED (NASDAQ ABMD)
Community Ranking:  3.0 out of 5 (  )
Outperform Votes:  244 (Vote Outperform)
Underperform Votes:  162 (Vote Underperform)
Total Votes:  406
MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ABIOMED (NASDAQ:ABMD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $157.50 (1.94% upside)

Analysts' Ratings History for ABIOMED (NASDAQ:ABMD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/4/2017Jefferies Group LLCBoost Price TargetBuy$165.00 -> $175.00LowView Rating Details
7/27/2017Piper Jaffray CompaniesReiterated RatingOverweight$145.00 -> $160.00MediumView Rating Details
7/10/2017Morgan StanleyReiterated RatingEqual Weight$135.00 -> $140.00LowView Rating Details
6/8/2017William BlairReiterated RatingOutperform -> OutperformLowView Rating Details
3/30/2017Leerink SwannBoost Price TargetOutperform$140.00 -> $150.00LowView Rating Details
1/8/2017BTIG ResearchReiterated RatingBuy$170.00N/AView Rating Details
12/6/2016GuggenheimInitiated CoverageBuy$150.00N/AView Rating Details
4/10/2016Benchmark Co.Reiterated RatingBuy$145.00N/AView Rating Details
10/30/2015Raymond James Financial, Inc.UpgradeMarket Perform -> Outperform$85.00N/AView Rating Details
10/29/2015Sterne Agee CRTReiterated RatingBuyN/AView Rating Details
8/17/2015CRT CapitalInitiated CoverageBuyN/AView Rating Details
(Data available from 8/16/2015 forward)

Earnings

Earnings History for ABIOMED (NASDAQ:ABMD)
Earnings by Quarter for ABIOMED (NASDAQ:ABMD)
Earnings History by Quarter for ABIOMED (NASDAQ ABMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$0.36N/AView Earnings Details
7/27/2017Q1 2018$0.42$0.45$130.83 million$132.47 millionViewN/AView Earnings Details
5/4/2017Q4 2017$0.33$0.33$122.82 million$124.68 millionViewListenView Earnings Details
1/26/2017Q317$0.29$0.34$112.71 million$114.70 millionViewListenView Earnings Details
10/27/2016Q217$0.24$0.20$103.16 million$103.00 millionViewListenView Earnings Details
7/28/2016Q117$0.23$0.29$97.23 million$103.00 millionViewListenView Earnings Details
5/3/2016Q416$0.19$0.24$90.52 million$94.00 millionViewN/AView Earnings Details
2/4/2016Q316$0.15$0.23$80.04 million$85.80 millionViewListenView Earnings Details
10/29/2015Q2$0.13$0.17$74.56 million$76.30 millionViewListenView Earnings Details
8/4/2015Q116$0.08$0.20$66.27 million$73.40 millionViewN/AView Earnings Details
5/5/2015Q415$0.12$0.28$62.55 million$67.60 millionViewN/AView Earnings Details
1/27/2015Q315$0.03$0.30$53.20 million$62.00 millionViewN/AView Earnings Details
10/30/2014Q215$0.02$0.09$48.80 million$51.80 millionViewN/AView Earnings Details
7/31/2014Q115$0.02($0.04)$297.10 million$48.80 millionViewN/AView Earnings Details
5/1/2014Q414$0.09$0.09$50.93 million$50.40 millionViewN/AView Earnings Details
1/31/2014Q314$0.05$0.11$46.00 million$46.20 millionViewN/AView Earnings Details
11/6/2013Q214$0.03$0.03$43.75 million$44.30 millionViewN/AView Earnings Details
8/1/2013Q1 2014$0.06($0.04)$42.93 million$42.70 millionViewN/AView Earnings Details
5/2/2013Q4 2013$0.08$0.09$41.87 million$43.70 millionViewN/AView Earnings Details
2/6/2013Q3 2013$0.07$0.07$38.04 million$38.30 millionViewN/AView Earnings Details
11/1/2012Q213$0.05$0.20$37.47 million$37.40 millionViewN/AView Earnings Details
8/2/2012$0.10$0.16ViewN/AView Earnings Details
5/16/2012$0.07$0.07ViewN/AView Earnings Details
2/3/2012($0.01)$0.07ViewN/AView Earnings Details
11/3/2011($0.09)$0.02ViewN/AView Earnings Details
8/4/2011($0.06)($0.03)ViewN/AView Earnings Details
5/18/2011($0.04)($0.05)ViewN/AView Earnings Details
2/3/2011($0.09)($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ABIOMED (NASDAQ:ABMD)
2017 EPS Consensus Estimate: $1.09
2018 EPS Consensus Estimate: $1.78
2019 EPS Consensus Estimate: $2.47
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20176$0.20$0.29$0.24
Q2 20173$0.22$0.24$0.23
Q3 20173$0.29$0.31$0.30
Q4 20172$0.32$0.32$0.32
Q1 20183$0.40$0.43$0.41
Q2 20183$0.32$0.38$0.35
Q3 20183$0.46$0.50$0.48
Q4 20183$0.50$0.61$0.55
Q1 20192$0.58$0.61$0.60
Q2 20191$0.51$0.51$0.51
Q3 20191$0.63$0.63$0.63
Q4 20192$0.65$0.82$0.74
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ABIOMED (NASDAQ:ABMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ABIOMED (NASDAQ:ABMD)
Insider Ownership Percentage: 7.00%
Institutional Ownership Percentage: 91.09%
Insider Trades by Quarter for ABIOMED (NASDAQ:ABMD)
Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)
Insider Trades by Quarter for ABIOMED (NASDAQ:ABMD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/31/2017David M WeberCOOSell16,500$147.63$2,435,895.00View SEC Filing  
5/16/2017Michael G HowleyVPSell18,279$133.56$2,441,343.24View SEC Filing  
5/8/2017David M WeberCOOSell21,250$130.89$2,781,412.50View SEC Filing  
5/8/2017Dorothy E PuhyDirectorSell13,500$131.12$1,770,120.00View SEC Filing  
5/8/2017Michael G HowleyVPSell600$132.84$79,704.00View SEC Filing  
3/17/2017Andrew J GreenfieldVPSell10,000$124.00$1,240,000.00View SEC Filing  
12/13/2016Dorothy E PuhyDirectorSell8,000$120.00$960,000.00View SEC Filing  
11/30/2016Eric A Md RoseDirectorSell8,000$110.81$886,480.00View SEC Filing  
9/22/2016Michael R MinogueCEOSell28,039$127.07$3,562,915.73View SEC Filing  
9/21/2016Michael R MinogueCEOSell5,034$127.07$639,670.38View SEC Filing  
9/19/2016Michael R MinogueCEOSell58,710$127.00$7,456,170.00View SEC Filing  
8/15/2016Dorothy E PuhyDirectorSell5,160$123.94$639,530.40View SEC Filing  
8/10/2016Dorothy E PuhyDirectorSell3,900$122.31$477,009.00View SEC Filing  
8/8/2016Michael G HowleyVPSell17,853$119.20$2,128,077.60View SEC Filing  
8/1/2016Henri A TermeerDirectorSell25,866$118.70$3,070,294.20View SEC Filing  
6/29/2016Michael G HowleyVPSell10,000$106.58$1,065,800.00View SEC Filing  
6/7/2016Andrew J GreenfieldVPSell9,000$104.16$937,440.00View SEC Filing  
5/23/2016David M WeberCOOSell4,342$96.97$421,043.74View SEC Filing  
5/16/2016David M WeberCOOSell5,604$94.56$529,914.24View SEC Filing  
5/6/2016David M WeberCOOSell2,145$93.82$201,243.90View SEC Filing  
5/5/2016David M WeberCOOSell52,000$95.27$4,954,040.00View SEC Filing  
5/5/2016Paul ThomasDirectorSell7,500$95.14$713,550.00View SEC Filing  
4/18/2016Andrew J GreenfieldVPSell10,000$99.10$991,000.00View SEC Filing  
4/13/2016Michael G HowleyVPSell9,800$98.64$966,672.00View SEC Filing  
4/8/2016Michael G HowleyVPSell200$98.80$19,760.00View SEC Filing  
4/1/2016Dorothy E PuhyDirectorSell10,000$95.02$950,200.00View SEC Filing  
3/31/2016Andrew J GreenfieldVPSell15,000$94.11$1,411,650.00View SEC Filing  
3/24/2016David M WeberCOOSell5,235$89.93$470,783.55View SEC Filing  
3/22/2016Andrew J GreenfieldVPSell24,800$89.06$2,208,688.00View SEC Filing  
3/22/2016Dorothy E PuhyDirectorSell10,000$90.30$903,000.00View SEC Filing  
3/21/2016Andrew J GreenfieldVPSell19,572$89.07$1,743,278.04View SEC Filing  
3/10/2016Andrew J GreenfieldVPSell200$89.00$17,800.00View SEC Filing  
3/8/2016David M WeberCOOSell17,521$85.20$1,492,789.20View SEC Filing  
3/8/2016William J BoltSVPSell17,510$85.19$1,491,676.90View SEC Filing  
3/7/2016David M WeberCOOSell8,111$85.21$691,138.31View SEC Filing  
3/7/2016Dorothy E PuhyDirectorSell4,000$85.00$340,000.00View SEC Filing  
3/7/2016William J BoltSVPSell7,987$85.20$680,492.40View SEC Filing  
2/8/2016Dorothy E. PuhyDirectorSell4,000$80.47$321,880.00View SEC Filing  
8/19/2015Michael R. MinogueCEOSell146,800$104.87$15,394,916.00View SEC Filing  
8/17/2015Dorothy E PuhyDirectorSell2,580$103.91$268,087.80View SEC Filing  
8/14/2015Dorothy E PuhyDirectorSell2,580$105.27$271,596.60View SEC Filing  
7/17/2015Michael G HowleyVPSell21,295$70.00$1,490,650.00View SEC Filing  
6/15/2015Andrew J GreenfieldVPSell3,185$65.00$207,025.00View SEC Filing  
5/29/2015Martin P SutterDirectorBuy7,500$60.17$451,275.00View SEC Filing  
5/27/2015David M WeberCOOSell17,968$60.77$1,091,915.36View SEC Filing  
5/12/2015Michael G HowleyVPSell17,353$66.47$1,153,453.91View SEC Filing  
5/7/2015Andrew J GreenfieldVPSell3,500$71.00$248,500.00View SEC Filing  
5/7/2015Robert BowenCFOSell2,372$71.52$169,645.44View SEC Filing  
5/6/2015David M WeberCOOSell1,605$73.72$118,320.60View SEC Filing  
5/6/2015Michael R MinogueCEOSell8,840$73.12$646,380.80View SEC Filing  
5/6/2015William J BoltSVPSell1,750$74.27$129,972.50View SEC Filing  
3/23/2015David M WeberCOOSell3,765$71.08$267,616.20View SEC Filing  
10/31/2014Andrew J GreenfieldVPSell15,000$31.90$478,500.00View SEC Filing  
10/31/2014Michael R MinogueCEOSell164,000$31.14$5,106,960.00View SEC Filing  
7/28/2014Michael R MinogueCEOSell82,383$26.30$2,166,672.90View SEC Filing  
5/27/2014Andrew J GreenfieldVPSell7,026$21.10$148,248.60View SEC Filing  
5/27/2014David M WeberCOOSell10,172$21.11$214,730.92View SEC Filing  
5/27/2014Michael R MinogueCEOSell90,001$21.19$1,907,121.19View SEC Filing  
5/27/2014Robert BowenCFOSell6,820$21.11$143,970.20View SEC Filing  
5/27/2014William J BoltSVPSell8,029$21.10$169,411.90View SEC Filing  
5/15/2014David WeberCOOSell1,425$20.94$29,839.50View SEC Filing  
5/15/2014Michael HowleyVPSell1,267$20.94$26,530.98View SEC Filing  
5/15/2014Michael MinogueCEOSell4,433$20.94$92,827.02View SEC Filing  
5/15/2014William BoltSVPSell1,110$20.94$23,243.40View SEC Filing  
1/10/2014Robert BowenCFOSell37,500$30.00$1,125,000.00View SEC Filing  
9/3/2013David WeberCOOSell6,500$24.00$156,000.00View SEC Filing  
9/3/2013William BoltSVPSell20,000$24.00$480,000.00View SEC Filing  
8/14/2013William BoltSVPSell21,534$23.35$502,818.90View SEC Filing  
8/13/2013David WeberCOOSell4,400$23.00$101,200.00View SEC Filing  
8/13/2013Michael HowleyVPSell8,400$23.00$193,200.00View SEC Filing  
8/5/2013David WeberCOOSell7,100$22.90$162,590.00View SEC Filing  
8/5/2013Michael HowleyVPSell1,600$23.03$36,848.00View SEC Filing  
8/5/2013Robert BowenCFOSell2,235$22.64$50,600.40View SEC Filing  
8/5/2013W Gerald AustenDirectorSell8,000$22.85$182,800.00View SEC Filing  
8/5/2013William BoltSVPSell20,166$22.70$457,768.20View SEC Filing  
7/31/2013Michael R MinogueCEOSell36,500$25.04$913,960.00View SEC Filing  
7/17/2013Michael G HowleyVPSell10,000$24.45$244,500.00View SEC Filing  
7/15/2013Robert BowenCFOSell40,786$23.50$958,471.00View SEC Filing  
7/11/2013Robert BowenCFOSell1,499$23.50$35,226.50View SEC Filing  
6/4/2013David M WeberCOOSell6,519$21.20$138,202.80View SEC Filing  
6/4/2013Michael G HowleyVPSell3,881$21.20$82,277.20View SEC Filing  
6/4/2013Michael R MinogueCEOSell17,667$21.23$375,070.41View SEC Filing  
6/4/2013Robert BowenCFOSell5,298$21.20$112,317.60View SEC Filing  
6/4/2013William J BoltSVPSell4,967$21.20$105,300.40View SEC Filing  
5/29/2013Michael R MinogueCEOSell58,833$21.83$1,284,324.39View SEC Filing  
5/28/2013David M WeberCOOSell6,018$22.18$133,479.24View SEC Filing  
5/28/2013Michael G HowleyVPSell5,476$22.18$121,457.68View SEC Filing  
5/28/2013Robert BowenCFOSell5,102$22.18$113,162.36View SEC Filing  
5/28/2013William J BoltSVPSell4,629$22.18$102,671.22View SEC Filing  
5/23/2013Andrew J GreenfieldVPSell1,666$21.63$36,035.58View SEC Filing  
5/23/2013Michael R MinogueCEOSell5,666$21.62$122,498.92View SEC Filing  
5/17/2013Robert BowenCFOSell2,715$23.50$63,802.50View SEC Filing  
5/9/2013Michael R MinogueCEOSell20,000$21.00$420,000.00View SEC Filing  
5/7/2013Henri A TermeerDirectorBuy100,000$19.86$1,986,000.00View SEC Filing  
2/25/2013Henri A TermeerDirectorBuy100,000$14.98$1,498,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ABIOMED (NASDAQ:ABMD)
Latest Headlines for ABIOMED (NASDAQ:ABMD)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to ABIOMED, Inc. : August 15, 2017
finance.yahoo.com - August 15 at 3:35 PM
finance.yahoo.com logoIHS Markit Score Update: Drop in demand for ETFs holding Abiomed Inc is a negative sign for its shares
finance.yahoo.com - August 12 at 1:41 AM
finance.yahoo.com logoWhy ABIOMED (ABMD) Could Be Positioned for a Surge
finance.yahoo.com - August 10 at 4:49 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Abiomed Inc.
finance.yahoo.com - August 9 at 8:36 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - August 7 at 1:42 PM
americanbankingnews.com logo$130.37 Million in Sales Expected for ABIOMED, Inc. (ABMD) This Quarter
www.americanbankingnews.com - August 7 at 7:44 AM
americanbankingnews.com logoABIOMED, Inc. (NASDAQ:ABMD) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - August 6 at 8:12 AM
americanbankingnews.com logo Brokerages Expect ABIOMED, Inc. (NASDAQ:ABMD) to Announce $0.37 EPS
www.americanbankingnews.com - August 5 at 10:38 PM
finance.yahoo.com logoPerkinElmer (PKI) Meets Q2 Earnings, Raises '17 Guidance
finance.yahoo.com - August 4 at 3:23 PM
finance.yahoo.com logoAllscripts (MDRX) Meets Q2 Earnings Estimates, View Upbeat
finance.yahoo.com - August 4 at 3:23 PM
finance.yahoo.com logoABIOMED, Inc. :ABMD-US: Earnings Analysis: Q1, 2018 By the Numbers : August 2, 2017
finance.yahoo.com - August 2 at 8:22 PM
americanbankingnews.com logoABIOMED, Inc. (NASDAQ:ABMD) COO Sells $2,435,895.00 in Stock
www.americanbankingnews.com - August 2 at 7:26 PM
finance.yahoo.com logoDexCom (DXCM) Q2 Loss Narrower Than Expected, Revenues Beat
finance.yahoo.com - August 2 at 3:19 PM
finance.yahoo.com logoCardinal Health (CAH) Q4 Earnings Beat Estimates, Rise Y/Y
finance.yahoo.com - August 2 at 3:19 PM
finance.yahoo.com logoQuality Systems (QSII) Beats on Q1 Earnings, Revenues
finance.yahoo.com - August 2 at 3:19 PM
americanbankingnews.com logoQ4 2018 EPS Estimates for ABIOMED, Inc. Lifted by Leerink Swann (NASDAQ:ABMD)
www.americanbankingnews.com - July 31 at 10:06 AM
americanbankingnews.com logoWilliam Blair Research Analysts Lift Earnings Estimates for ABIOMED, Inc. (NASDAQ:ABMD)
www.americanbankingnews.com - July 31 at 9:04 AM
nasdaq.com logoAbiomed (ABMD) Q1 Earnings and Revenues Beat Estimates - Nasdaq
www.nasdaq.com - July 28 at 3:39 PM
finance.yahoo.com logoAbiomed (ABMD) Q1 Earnings and Revenues Beat Estimates
finance.yahoo.com - July 28 at 3:39 PM
fool.com logoAbiomed, Inc. Starts Its Fiscal Year on a High Note
www.fool.com - July 28 at 9:20 AM
finance.yahoo.com logoInvestor Network: ABIOMED, Inc. to Host Earnings Call
finance.yahoo.com - July 27 at 8:33 PM
finance.yahoo.com logoAbiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year
finance.yahoo.com - July 27 at 8:33 PM
finance.yahoo.com logoEdited Transcript of ABMD earnings conference call or presentation 27-Jul-17 12:00pm GMT
finance.yahoo.com - July 27 at 8:33 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Issues Earnings Results
www.americanbankingnews.com - July 27 at 4:59 PM
americanbankingnews.com logoPiper Jaffray Companies Reiterates "Overweight" Rating for ABIOMED, Inc. (NASDAQ:ABMD)
www.americanbankingnews.com - July 27 at 4:50 PM
finance.yahoo.com logoAbiomed beats Street 1Q forecasts
finance.yahoo.com - July 27 at 3:24 PM
nasdaq.com logoCheck Out 5 Profitable Stocks for Spectacular Gains - Nasdaq.com - Nasdaq
www.nasdaq.com - July 26 at 3:17 PM
nasdaq.com logoABIOMED Reaches Analyst Target Price - Nasdaq.com - Nasdaq
www.nasdaq.com - July 26 at 3:17 PM
finance.yahoo.com logoWhere Abiomed Plans to Expand Impella CP’s Label
finance.yahoo.com - July 25 at 3:20 PM
finance.yahoo.com logoUnderstanding Abiomed’s Changing Payment Structure Plans for Impella
finance.yahoo.com - July 25 at 3:20 PM
finance.yahoo.com logoWhy Abiomed Expects to Benefit from Impella in Cardiogenic Shock
finance.yahoo.com - July 24 at 2:00 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 24 at 10:16 AM
finance.yahoo.com logoAbiomed Aims to Expand Impella RP’s Penetration Going Forward
finance.yahoo.com - July 21 at 9:40 PM
finance.yahoo.com logoAbiomed Impella Quality Program Will Boost Demand in Fiscal 2018
finance.yahoo.com - July 21 at 4:37 PM
finance.yahoo.com logoAbiomed in 2017: The Analysts’ View
finance.yahoo.com - July 20 at 8:19 PM
americanbankingnews.com logoABIOMED, Inc. (NASDAQ:ABMD) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - July 20 at 7:02 AM
americanbankingnews.com logo$129.70 Million in Sales Expected for ABIOMED, Inc. (NASDAQ:ABMD) This Quarter
www.americanbankingnews.com - July 16 at 8:00 AM
americanbankingnews.com logo$0.42 Earnings Per Share Expected for ABIOMED, Inc. (NASDAQ:ABMD) This Quarter
www.americanbankingnews.com - July 14 at 6:20 PM
finance.yahoo.com logoAbbott Partners Bigfoot Biomedical to Expand in Diabetics
finance.yahoo.com - July 14 at 5:10 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - July 13 at 4:52 PM
nasdaq.com logoAbiomed (ABMD) Scores a Strong Buy Right Now: Here's How
www.nasdaq.com - July 13 at 3:44 PM
finance.yahoo.com logoAbiomed (ABMD) Scores a Strong Buy Right Now: Here's How
finance.yahoo.com - July 13 at 3:44 PM
finance.yahoo.com logoETFs with exposure to ABIOMED, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 3:44 PM
americanbankingnews.com logoABIOMED, Inc. (NASDAQ:ABMD) Stock Rating Reaffirmed by Morgan Stanley
www.americanbankingnews.com - July 10 at 11:32 PM
globenewswire.com logoAbiomed First Quarter Fiscal 2018 Earnings and Conference Call Notification - GlobeNewswire (press release)
globenewswire.com - July 6 at 4:46 PM
feeds.benzinga.com logoAbiomed First Quarter Fiscal 2018 Earnings and Conference Call Notification
feeds.benzinga.com - July 6 at 7:38 AM
americanbankingnews.com logoZacks Investment Research Downgrades ABIOMED, Inc. (NASDAQ:ABMD) to Hold
www.americanbankingnews.com - July 5 at 2:06 PM
globenewswire.com logoNew Study with Abiomed's Impella 2.5® Heart Pump Demonstrates ... - GlobeNewswire (press release)
globenewswire.com - July 1 at 1:40 AM
nasdaq.com logoNew Study with Abiomed's Impella 2.5® Heart Pump Demonstrates Potential Survival with Pre-PCI Insertion in Heart ... - Nasdaq
www.nasdaq.com - June 30 at 3:24 PM
finance.yahoo.com logoNew Study with Abiomed's Impella 2.5® Heart Pump Demonstrates Potential Survival with Pre-PCI Insertion in Heart Attacks with the Left Main Coronary Artery
finance.yahoo.com - June 30 at 3:24 PM

Social

Chart

ABIOMED (ABMD) Chart for Wednesday, August, 16, 2017

This page was last updated on 8/16/2017 by MarketBeat.com Staff